Pharmacological targeting of melanoma differentiation-associated gene 9 (MDA-9/Syntenin) by PDZ1i inhibited radiation-induced invasion and radiosensitized GBM in vitro and in vivo [52]. This evidence concerns the gene SDCBP and glioblastoma.